HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...
A research group led by Assistant Professor Megumi Aimoto and Professor Akira Takahara at the Faculty of Pharmaceutical Sciences, Toho University, revealed that pyrazole-3 (Pyr3), a selective ...
AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback